Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 10.77 -3.49% -0.39
DRNA closed down 3.49 percent on Friday, January 18, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DRNA trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 17 Crossed Above 20 DMA Bullish -3.49%
Jan 16 20 DMA Resistance Bearish 0.94%
Jan 16 180 Bearish Setup Bearish Swing Setup 0.94%
Jan 15 20 DMA Resistance Bearish -0.92%
Jan 14 Down 3 Days in a Row Weakness 3.66%
Jan 14 Gapped Down Weakness 3.66%
Jan 11 Fell Below 20 DMA Bearish -2.80%
Jan 11 180 Bearish Setup Bearish Swing Setup -2.80%

Older signals for DRNA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Is DRNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.98
52 Week Low 8.71
Average Volume 548,206
200-Day Moving Average 13.3359
50-Day Moving Average 12.508
20-Day Moving Average 10.8655
10-Day Moving Average 11.088
Average True Range 0.8168
ADX 16.8
+DI 16.512
-DI 18.7308
Chandelier Exit (Long, 3 ATRs ) 9.7296
Chandelier Exit (Short, 3 ATRs ) 11.7604
Upper Bollinger Band 12.0696
Lower Bollinger Band 9.6614
Percent B (%b) 0.46
BandWidth 22.163729
MACD Line -0.3927
MACD Signal Line -0.4641
MACD Histogram 0.0714
Fundamentals Value
Market Cap 224.5 Million
Num Shares 20.8 Million
EPS -3.20
Price-to-Earnings (P/E) Ratio -3.37
Price-to-Sales 155.10
Price-to-Book 7.93
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.70
Resistance 3 (R3) 11.78 11.55 11.55
Resistance 2 (R2) 11.55 11.31 11.51 11.49
Resistance 1 (R1) 11.16 11.17 11.05 11.08 11.44
Pivot Point 10.93 10.93 10.87 10.89 10.93
Support 1 (S1) 10.54 10.69 10.43 10.46 10.10
Support 2 (S2) 10.31 10.55 10.27 10.05
Support 3 (S3) 9.92 10.31 10.00
Support 4 (S4) 9.84